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Background This study assessed the effects of two doses of glucose and a caffeine–glucose combination on mood and performance of an
ecologically valid, computerised multi-tasking platform.
Materials and methods Following a double-blind, placebo-controlled, randomised, parallel-groups design, 150 healthy adults (mean age
34.78 years) consumed drinks containing placebo, 25 g glucose, 60 g glucose or 60 g glucose with 40mg caffeine. They completed a multi-
tasking framework at baseline and then 30min following drink consumption with mood assessments immediately before and after the multi-
tasking framework. Blood glucose and salivary caffeine were co-monitored.
Results The caffeine–glucose group had signiﬁcantly better total multi-tasking scores than the placebo or 60 g glucose groups and were
signiﬁcantly faster at mental arithmetic tasks than either glucose drink group. There were no signiﬁcant treatment effects on mood. Caffeine
and glucose levels conﬁrmed compliance with overnight abstinence/fasting, respectively, and followed the predicted post-drink patterns.
Conclusion These data suggest that co-administration of glucose and caffeine allows greater allocation of attentional resources than
placebo or glucose alone. At present, we cannot rule out the possibility that the effects are due to caffeine alone Future studies should aim
at disentangling caffeine and glucose effects. © 2014 The Authors. Human Psychopharmacology: Clinical and Experimental published
by John Wiley & Sons, Ltd.
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INTRODUCTION
Caffeine and glucose are two of the most widely
consumed centrally active substances in the world.
Caffeine (and to a lesser extent glucose) are used partly
because of their potential cognition-enhancing proper-
ties. Although they are often co-consumed, including
increasingly in the form of energy drinks, there is
surprisingly little research examining the effects of
the two substances in combination in the context of
neurocognitive function.
The mood and cognitive effects of caffeine have
been comprehensively reviewed elsewhere (Glade,
2010; Rogers et al., 2011; Smith, 2002). Typically, ad-
ministration of caffeine in the range of 50 to 150mg
improves reaction times, psychomotor function,
attention, vigilance and alertness-with the effects
being particularly evident in fatigued individuals.
Lower doses of caffeine have been less thoroughly
researched, but doses as low as 12.5mg, a level
roughly equivalent to half a serving of cola, have been
shown to be psychopharmacologically active (Smit
and Rogers, 2000).
Glucose is the primary source of energy for the brain
and, as such, is essential for central nervous system
functioning. It has been extensively reported that cog-
nitive performance can be enhanced following admin-
istration of drinks containing 25-50 g glucose. The
effect is most apparent on tasks with a declarative
memory component and/or those with heavier cogni-
tive demands (Benton et al., 1994; Donohoe and
Benton, 1999; Riby, 2004; Scholey et al., 2009b;
Scholey and Fowles, 2002; Scholey et al., 2001;
Sünram-Lea et al., 2008), including dual tasking
(Foster et al., 1998; Scholey et al., 2009b; Smith et al.,
2011; Sünram-Lea et al., 2002; Scholey et al., 2013).
Despite the abundance of studies investigating the
behavioural effects of the two substances individually,
there is surprisingly little research evaluating the mood
and cognitive effects of caffeine and glucose both
separately and together. This has been given further
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impetus from the fact that they are increasingly con-
sumed concomitantly in so-called energy drinks.
One recent study investigating the combined and
separate effects of 75 g glucose and 75mg caffeine
revealed beneﬁcial effects to both sustained attention
and learning from the combination (Adan and Serra
Grabulosa, 2010). These effects were not observed in
either the caffeine-only or glucose-only condition. In
a follow-up study that used the same doses and
included a functional magnetic resonance imaging
component, the same group found no differences in
performance of an attentional task between glucose,
caffeine and their combination (Serra Grabulosa
et al., 2010). Functional imaging during task perfor-
mance, however, revealed lower activation of parietal
and prefrontal cortices in the caffeine–glucose condi-
tion. These ﬁndings can be interpreted as suggesting
that the caffeine–glucose drink increased ‘neural efﬁ-
ciency’, such that less brain activation was required
to maintain a level of cognitive performance.
The doses used in both the aforementioned studies
were 75 g glucose and 75mg caffeine. This caffeine
level is consistentwith, for example, coffee, which typically
contains between 50 and 100mg caffeine. Energy drinks
can also contain caffeine in the range of 75 to 200mg
caffeine or more per serving. Some, however, have lower
levels more typical of colas (35–45mg).
Regarding the amount of glucose used in the Adan
and Serra Grabulosa studies, 75 g is far higher than
the levels found in sweetened coffee or tea. It is also
higher than the 25–50 g used in studies into glucose
effects on cognition (Riby, 2004) and is relatively high
compared with many caffeinated beverages such as
energy drinks, which typically contain around half this
amount.
Earlier studies have examined the cognitive effects
of glucose and caffeine at levels more typical of every-
day consumption. Compared with a glucose-and-
caffeine-free control, drinks containing glucose/
caffeine at both 68 g/38mg and 68 g/46mg improved
performance during sustained, cognitively demanding
tasks (Kennedy and Scholey, 2004). Other studies in-
dicate an additive or even synergistic effect between
caffeine and glucose on various domains of cognition.
In separate studies, 37.5 g glucose, 75mg caffeine
drinks improved sustained attention, working memory
(Smit et al., 2004), declarative memory and speed of
attention (Scholey and Kennedy, 2004) above levels
of either substance alone.
The distribution of attentional resources over multiple
tasks engages a number of mental processes that
increase cognitive demand relative to a single task
performance. Moreover, the ability to effectively and
accurately multi-task has great utility in planning and
decision making in everyday life. Interventions that
have the capacity to improve these cognitive abilities
are therefore of interest both scientiﬁcally and practi-
cally. The current study was therefore designed to assess
the potential effects of glucose (two doses, 25 and 60 g)
and a caffeine–glucose combination (60 g glucose,
40mg caffeine) on cognitive performance and mood
associated with cognitive multi-tasking. Speciﬁcally, it
aimed to investigate effects on ‘everyday’ cognition
using a multi-tasking framework (MTF)—comprising
four tasks completed simultaneously—and on mood
ratings taken before and after completion of the MTF.
Two main hypotheses were tested. The primary
hypothesis was that, compared with placebo, caffeine–
glucose in combination would result in improved cogni-
tive multi-tasking performance as measured by overall
MTF scores. We have previously argued that glucose
preferentially targets more mentally effortful cognitive
processes. Glucose is particularly effective at increasing
performance during effortful processing, including
during dual attention tasks (Scholey et al., 2009b;
Sünram-Lea et al., 2002). As dividing cognitive
resources over several tasks involves relatively high
mental effort, we hypothesised that the two doses of
glucose alone would also improve performance. The
secondary hypotheses were that, compared with
placebo and/or glucose alone, the caffeine–glucose
combination would improve task performance on indi-
vidual tasks from the MTF and improve subjective
feelings of mood, stress and fatigue during extended
cognitive multi-tasking.
METHODS
Design
The investigation was a single-centre, randomised,
double-blind, placebo-controlled, parallel-groups
study conducted at the Centre for Human Psychophar-
macology, Swinburne University, Australia. The study
was approved by the Swinburne University Human
Research Ethics Committee (ref SUHREC #2010/
299) and conducted in accordance with the Declaration
of Helsinki. All participants provided written informed
consent. The trial was registered on the Australian
New Zealand Clinical Trials Registry (ANZCTR) as
ACTRN12613000247774.
The study assessed the effects of two doses of glu-
cose alone (25 and 60 g) and one dose of a (40mg,
60 g) caffeine–glucose combination on cognitive
performance, fatigue, stress and mood associated with
extended multi-tasking.
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Participants
One hundred and sixty healthy adults (male and fe-
male) aged between 18 and 55 years were recruited
for the study. Participants were recruited from the in-
vestigators’ existing database and via local media ad-
vertising. All participants were healthy, non-smoking,
regular caffeine consumers with no signiﬁcant concur-
rent illnesses or a history of psychiatric disease.
Blood glucose measurement
Blood glucose levels were monitored using aMediSense
Optium Xceed Blood Glucose Sensor and disposable
MediSense Blood Glucose Electrodes (MediSense
Britain Ltd, Birmingham, UK). The accuracy and
consistency of MediSense blood glucose sensors have
previously been established (Matthews et al., 1987).
The reliability of the test has previously been conﬁrmed.
Blood samples were taken using Owen Mumford
‘Unistik 2’ single-use capillary blood sampling devices
(Owen Mumford Ltd, Oxford, UK). Alcohol-soaked
skin cleansing swabs (Briemarkap, KooWeeRup, Victoria,
Australia) were used for pre-sampling sterilisation.
Salivary caffeine measurement
Saliva samples were collected using salivettes. These
consist of a small test tube ﬁtted with an inner recepta-
cle containing a sterile cotton wool bud. Participants
were required to remove the cotton wool bud and place
it in the mouth, chewing gently for approximately
2min and then replacing it in the test tube. The test
tube with the saliva-cotton wool was then centrifuged,
and the sample frozen for analysis. Salivary caffeine
was measured using a caffeine immunoassay as previ-
ously described (Haskell et al., 2005).
Multi-tasking framework
A computerised MTF was used. This platform offers
relatively high ecological validity in terms of the
cognitive demands required to complete several dispa-
rate tasks simultaneously in the work environment
(Wetherell and Carter, 2013). The computerised MTF
comprises four cognitive and psychomotor tasks that
are undertaken simultaneously using a four-way split
screen.
Responses to all of the tasks are made using the
mouse and cursor. Completion of the battery for an ex-
tended period has been shown to induce stress-related
physiological processes (Wetherell and Sidgreaves,
2005) and to modulate subjective feelings of mood,
including decreased alertness and increased mental
fatigue and anxiety (Kennedy et al., 2004; Scholey
et al., 2009a). In terms of cognitive performance, the
MTF has also been shown to be sensitive to a number
of natural interventions, including food supplements
and herbal extracts (Kennedy et al., 2006; Kennedy
et al., 2004).
In this study, a 20-min version of the MTF was
employed with the framework set at medium
intensity (see Scholey et al., 2009a, for details). The
individual MTF tasks used here were as follows
(arranged clockwise from top left).
Mathematical processing task. A series of addition
calculations are presented. Each calculation requires
the participant to add two numbers together, entering
the three-ﬁgure answer via an onscreen number pad.
On completion of each calculation, the participant
clicks the ‘done’ button, which cues the next calcula-
tion. The outcomes are the speed of performance
(number of calculations completed in 20min) and ac-
curacy (% correct). The module also generates an over-
all score incorporating correct answers (+10 points)
and incorrect answers (10 points).
Stroop colour–word task. Words describing one of
four colours (‘RED’, ‘YELLOW’, ‘GREEN’ and
‘BLUE’) are presented in different coloured fonts. The
participant clicks on colour panels in order to identify
the font colour (e.g. if the word ‘GREEN’ is presented
in a blue font, the correct response would be to click
on the blue panel). If the participant fails to respond
within 20 s, the task times out and the stimulus is re-
placed. The outcomes are the speed of performance
(number of responses within 20min) and accuracy
(%correct). The module also generates an overall score
incorporating correct answers (+10 points), incorrect
answers (10 points) and timeouts (10 points).
Memory search task. Four letters appear for the partic-
ipants to remember. After 4 s, the letters disappear but
can be viewed again by clicking on ‘retrieve list’ but-
ton. Every 10 s, a single target letter appears. Partici-
pants are instructed to indicate whether the target
letter had appeared in the original list of four letters
by clicking on the ‘yes’ or ‘no’ buttons. If the partici-
pant fails to respond within 15 s, the task times out
and the stimulus is replaced. The outcomes are the
speed of performance (number of responses within
20min) and accuracy (% correct). The module also
generates an overall score incorporating the number
of responses (+10 points each), incorrect responses
(10 points) and timeouts (10 points).
Target tracker. A red dot moves slowly outwards
from the centre of target-shaped concentric circles hold
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(at a speed of approximately 3 s/cm). Participants must
click on one of two ‘reset’ buttons before the dot
reaches the outer circle in order to re-centre the dot.
Each larger circle increases the score by two points,
from two to a maximum of 10 points. The red dot will
begin to ﬂash when touching the outer circle if reset
buttons are not pressed, losing 10 points per 0.5 s until
a response is made. The outcomes are the speed of
performance (number of responses within 20min)
and accuracy (% correct). The module also generates
an overall score incorporating number of responses
and timeouts.
Pencil-and-paper measures
Bond–Lader visual analogue mood scales. The Bond
and Lader (1974) mood scales have been utilised in nu-
merous pharmacological, psychopharmacological and
medical trials. The measure comprises 16 × 100mm vi-
sual analogue mood scales with the endpoints anchored
by the following antonyms: alert–drowsy, calm–excited,
strong–feeble, muzzy–clearheaded, well coordinated–
clumsy, lethargic–energetic, contented–discontented,
troubled–tranquil, mentally slow–quick witted, tense–
relaxed, attentive–dreamy, incompetent–proﬁcient,
happy–sad, antagonistic–friendly, interested–bored and
withdrawn–sociable. Participants were presented with
a sheet of paper containing the scales and instructed to
mark their current mood state on each line. These are
combined as recommended by the authors to form three
mood factors, ‘alert’, ‘calm’ and ‘contented’, with scores
on each ranging from 0 to 100.
Stress and fatigue visual analogue mood scales. These
single visual analogue scales aim to gauge subjective
mood at the present moment. The items consist of sin-
gle 100-mm lines labelled ‘stress’ and ‘fatigue’ with
the endpoints labelled ‘not at all’ and ‘extremely’.
State-Trait Anxiety Inventory—State portion. The
State-Trait Anxiety Inventory (STAI; Spielberger
et al., 1970) comprises two scales. The ‘State’
(STAI-S) subscale is a widely used instrument for
measuring ﬂuctuating levels of anxiety. Participants
rate how much statements match their current state
by marking a 4-point scale ranging from not at all to
very much so. The subscale contains 20 statements
(e.g. ‘I am calm’). Scores range from 20 to 80, with
higher scores indicating more anxiety.
The National Aeronautics and Space Administration
Task Load Index perceived workload questionnaire.
The National Aeronautics and Space Administration
Task Load Index (NASA-TLX; Hart and Staveland,
1988) assesses work load. Participants rate the per-
ceived effort (from very low to very high) involved
in performing the MTF along six dimensions. Three
gauge the demand placed upon the respondent by the
task (mental demand, physical demand and temporal
demand), and three gauge elements of the interaction
between participant and task (effort, frustration and
perceived performance).
Treatments
On their study day, each participant received one of
four treatments supplied in the form of a 330ml
orange-ﬂavoured drink in unlabelled bottles in opaque
sleeves. The drinks comprised (i) placebo, a commercial
sugar-free ﬁzzy orange drink; (ii) 25 g glucose, in the form
of a fruit-ﬂavoured, carbonated drink (iii) 60 g glucose, in
a carbonated, fruit-ﬂavoured drink and (iv) caffeine–
glucose, in the form of a commercially available, fruit-
ﬂavoured, carbonated drink containing 40mg caffeine
and 60g glucose. Note that the glucose was in the form
of glucose syrup formulated to release 60 g of glucose
when broken down.
Randomisation to treatment was achieved by allocating
each individual to a condition as determined by a disin-
terested third party who played no other part in the study.
All products contained inactive commercially avail-
able food ingredients including sweeteners (sucralose/
acesulfame K), acidulant (malic acid), preservative
(potassium sorbate) and ﬂavourings. Each participant
was allowed 5min to consume one of the treatments
during their testing visit. Treatment bottles were placed
in identical sleeves before consumption to maintain the
double blind by preventing sighting of colour/texture
differences between the treatments by researcher or
participant.
Products were manufactured and supplied by GSK
Nutritional Healthcare R&D (Brentford, UK) who
monitored and approved chemical, sensorial and
microbiological stability of the products used on
study initiation and for the duration of the study. The
levels of caffeine were determined by analysis, and
conﬁrmed before the start of the study.
Procedure
Participants visited the laboratory on two occasions.
The ﬁrst was an initial practice session, where they
signed a participant informed consent form indicating
comprehension and compliance with study processes
and were allocated a study identiﬁcation number. Mor-
phometric and demographic data were recorded as well
as details of any relevant medical history and concom-
itant medications. The practice session also included
measures of personality and emotional intelligence
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(paper questionnaires) for purposes unrelated to the
current study. These included the Trait portion of the
Spielberger State-Trait Anxiety scale, the Proﬁle of
Mood States, the Swinburne University Emotional
Intelligence Test and the Neuroticism–Extroversion–
Openness Inventory Five Factor Inventory. Partici-
pants were familiarised with the mood questionnaires
including the Bond–Lader, STAI-S, visual analogue
scales and NASA-TLX and practiced completing the
computer-based cognitive MTF. This served to famil-
iarise subjects with task requirements and to attenuate
any practice effects.
The subsequent visit comprised the study days that
took place at least 24 h after the practice visit [mean
6.51 days, standard deviation (SD) 4.52]. Participants
were instructed to fast for 12 h prior to study days
and to abstain from drinking alcohol and caffeinated
drinks for 24 and 12 h, respectively. The study day
testing session lasted for 1.5 h. Upon arrival, partici-
pants provided blood and saliva for baseline fasted
glucose and caffeine measurement, respectively.
Following this, baseline mood, stress and fatigue
measures were completed immediately before and after
the computer-based MTF. The treatment drink was
then administered to the participant who was allowed
5min to consume the product. Exactly 30min later
(to allow for product absorption), a second blood
glucose measure was taken. Participants again
completed mood, fatigue and stress questionnaires
immediately before and after completion of the MTF.
After this session (60min post-dose), ﬁnal blood
glucose measurement and salivary samples were
provided. Participants were thanked and fully debriefed,
and they were asked to indicate which condition they
believed they had been in and then given the opportunity
to ask questions of the experimenter before leaving the
laboratory.
STATISTICS
Sample size calculation. Sample size was determined
on the basis of the data from Kennedy and Scholey
(2004). Mean change-from-baseline rapid visual infor-
mation processing accuracy scores were averaged
across the 30-, 40- and 50-min post-treatment mea-
sures for the 40 g caffeine plus 68 g glucose and the
placebo conditions, respectively. The resulting effect
size (Cohen’s d) of 0.372 was used to calculate the
sample size for a four-condition analysis of variance
(ANOVA) using G*POWER v3.12 (Faul et al., 2007).
This generated anN of 132 to detect a signiﬁcant difference
at an α level of 0.05 with 95% power. Given the
exploratory nature of this study, and the possibility of
attrition, theNwas increased to 40/cell in order to optimise
the chances of capturing treatment-related effects.
Data treatment and analysis. Data were analysed
using the statistical software SPSS v20 for Windows
unless otherwise stated.
Demographic and morphometric data were analysed
using one-way ANOVA comparing treatments with
pairwise comparisons where appropriate to ensure that
the groups were matched. Blood glucose levels were
analysed using a 2-way ANOVA examining effects of
Treatment ×Time (baseline, pre-testing, post-testing)
with the latter as a within-subjects factor. Salivary
caffeine was analysed using a 2-wayANOVA examining
effects of Treatment ×Time (pre-testing, post-testing)
with the latter as a within-subjects factor.
The primary outcome was the overall multi-tasking
score. Secondary outcomes included scores on the
individual tasks. Multi-tasking performance (overall
score and individual task scores) were analysed as
follows. Each score was computed as change from
baseline, group outliers were removed from resulting
scores and data were then analysed by one-way
ANOVA comparing treatments. Group differences
were explored by all pairwise comparisons (least
signiﬁcant difference statistic).
Mood and stress reactivity (i.e. the changes in alert-
ness, calmness, contentedness, state anxiety, stress and
fatigue) were computed (post-stressor minus pre-
stressor or Δ). The resulting scores were examined as
change from baseline Δ and were analysed by one-
way ANOVA in the same way as the performance
scores. Changes in aspects of perceived effort as mea-
sured using the NASA-TLX were analysed by one-way
ANOVA examining effects of treatment (drink). Planned
pairwise comparisons (least signiﬁcant difference) were
conducted to establish differences between active treat-
ments and placebo and between different active drinks.
Treatment guessing data were analysed by chi-square
comparing the distribution of treatment guesses to
chance within each condition using GRAPHPAD software
(GraphPad Software, La Jolla, CA).
RESULTS
Participant characteristics
Of 160 participants enrolled into the study, there were
150 suitable datasets for analysis. The ﬂow of partici-
pants through the study is presented in Figure 1.
Participants were non-smokers and regular caffeine
consumers (at least one caffeinated beverage per
day). Further demographic variables are presented in
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Table 1, and there were no group differences in any
demographic or morphometric measure.
Blood glucose
There was a signiﬁcant time × condition interaction for
blood glucose levels [F(6, 292) = 20.68, p< 0.001].
Blood glucose levels did not differ at baseline
[F(3, 146) = 0.91, p = 0.438]. There were signiﬁcant
group differences at both at the 30-min (pre-task)
[F(3, 146) = 25.48, p< 0.001] and 60-min (post-task)
[F(3, 146) = 27.21, p< 0.001] time points. Pairwise
comparisons revealed that all measures were signiﬁ-
cantly higher than placebo at both post-baseline time
points (p< 0.005) and that the 25 g drink was associated
with lower blood glucose levels than the caffeine–
glucose drink at the pre-task measure (p=0.038) and
both the 60 g drink and the caffeine–glucose drink at
the post-test measure (p< 0.005 in both cases). These
data are plotted in Figure 2 (upper panel).
Salivary caffeine
A threshold of 2000 ng/ml salivary caffeine was used
as a cut-off for compliance to overnight caffeine with-
drawal (Rogers et al., 2005). Compliance was high
with no exclusions owing to supra-threshold salivary
caffeine. There was, however, a high variability in
baseline caffeine levels ranging from sub-detection
levels to 1942 ng/ml.
There was a signiﬁcant Treatment × Time interaction
for salivary caffeine levels [F(3, 136) = 23.38,
p< 0.001]. Salivary caffeine levels did not differ at
baseline [F(3, 136) = 0.34, p= 0.798]. There were
signiﬁcant differences in the post-task samples
[F(3, 136) = 7.76, p< 0.001] compared with those in
the caffeine–glucose drink condition having signiﬁ-
cantly higher salivary caffeine levels than those in
the placebo, 25 g glucose and 60 g glucose condi-
tions (p< 0.005). These data are plotted in Figure 2
(lower panel).
Figure 1. Flow of participants through the study, including numbers screened, entered into the study, lost to data capture errors and analysed
Table 1. Demographic and morphometric characteristics of participants included in analysis
All Placebo 25 g glucose 60 g glucose Caffeine–glucose
N 150 37 38 39 36
M/F 58/92 12/25 17/21 14/25 15/21
Age 34.78 (10.63) 30.51 (10.00) 31.85 (11.02) 31.44 (10.32) 34.78 (11.09)
BMI 24.36 (4.45) 24.70 (4.05) 24.10 (5.22) 23.97 (3.65) 24.72 (4.86)
Years education 17.24 (3.02) 17.00 (2.56) 17.44 (3.44) 16.95 (2.71) 17.58 (3.33)
Overall Ns and numbers of male/female (M/F) adults are shown along with mean (with standard deviation) age, body mass index (BMI), and years
of education.
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Multi-tasking and mood
To ensure that the MTF had the established effects on
self-rated mood, mood scores collected pre- and post-
MTF were subjected to a three-way Treatment ×Time
(baseline, post-treatment) ×MTF (pre-, post-) ANOVA.
Independent of any treatment effects, the MTF had the
expected effect on mood as reﬂected by signiﬁcant
main effects of MTF associated with signiﬁcantly
decreased calmness [F(1, 146) = 7.56, p = 0.007] and
contentment [F(1, 146) = 47.83, p< 0.001], coupled
with increased stress [F(1, 146) = 34.90, p< 0.001],
fatigue [F(1, 146) = 79.50, p< 0.001] and state anxiety
[F(1, 146) = 13.13, p< 0.001].
Prior to analysing treatment effects, each outcome
measure was subject to a one-way ANOVA comparing
pre-treatment baseline scores in each treatment group
(presented in Table 2). There were no signiﬁcant
differences.
Regarding post-treatment effects, there was a signif-
icant main effect of treatment on the primary outcome
variable, namely the overall multi-tasking score
[F(3, 146) = 3.56, p = 0.015]. Pairwise comparisons
revealed a signiﬁcant difference between placebo and
the caffeine–glucose drink (p= 0.005), and between
the 60 g glucose and the glucose + caffeine drinks
(p= 0.006)—see Figure 3. There was a signiﬁcant
main effect of treatment on speed of performing the
mathematical reasoning task [F(3, 145) = 4.14,
p = 0.008]. The glucose + caffeine group performed
signiﬁcantly faster than the 25 g glucose group
(p= 0.034) and the 60 g glucose group (p = 0.001).
There was a trend for a treatment effect for speed of
responding on the Stroop task [F(3, 143) = 2.62,
p = 0.054]. The caffeine–glucose drink was associated
with faster responses than the placebo and the 60 g
glucose drink [p= 0.027 and p = 0.011, respectively].
There were no signiﬁcant treatment effects on mood
measures or perceived effort as gauged using the
NASA-TLX. Mean scores for the mood measures and the
NASA-TLX are presented in Tables 3 and 4, respectively.
Treatment guessing
Overall, there was a signiﬁcant bias towards guessing
the glucose conditions [χ2(3) = 17.093, p= 0.0007]
with 38.67% and 25.33% guessing that they had re-
ceived 25 and 60 g glucose, respectively, compared
with 18% each guessing they had received the placebo
and caffeine–glucose drinks. Within each condition,
however, the distribution of guesses did not differ signif-
icantly for the placebo [χ2(3) = 0.407, ns], 25 g glucose
[χ2(3) = 0.897, ns], 60 g glucose [χ2(3) = 3.684, ns] or
caffeine–glucose [χ2(3) = 5.444, ns] (Table 5).
There were no adverse events.
DISCUSSION
Supporting our hypothesis, there was a signiﬁcant
treatment effect on multi-tasking performance with
those in the caffeine–glucose drink outperforming the
placebo condition. Multi-tasking performance was also
signiﬁcantly better in the caffeine–glucose condition
than in the 60 g glucose drink condition. These data
are consistent with the hypothesis that a caffeine–
glucose drink can increase the amount of attentional re-
sources, which can be allocated to task performance.
This is in broad agreement with the results of a func-
tional magnetic resonance imaging study showing lower
levels of neural activation following a caffeine–glucose
combination (albeit at different levels) than placebo or
caffeine or glucose alone (Serra Grabulosa et al., 2010).
Regarding the mechanisms underlying superior
multi-tasking, we can be conﬁdent that the double
blind was effective and that expectations as to condi-
tions did not inﬂuence results. Treatment guessing
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Figure 2. Mean± standard error of mean blood glucose levels (top)
and salivary caffeine levels (bottom). For blood glucose a, signiﬁcantly
different to all other drink conditions; b, signiﬁcantly different from
caffeine–glucose; c, signiﬁcantly different from 60 g glucose and caffeine–
glucose at same time point. For salivary caffeine levels ***p< 0.005 at same
time point
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Table 2. Summary statistics showing treatment effects (mean and SD) on multi-tasking measures
Baseline Post-treatment Change from baseline
Mean SD Mean SD Mean SD
Multi-tasking scorea Placebo 8596 2756 9228 3006 632 1003
25 g glucose 8859 2436 9848 2538 989 1195
60 g glucose 8754 2654 9422 2528 668 1179
Caffeine–glucose 9530 2277 10 999 2470 1469 1538
Mathematical reasoning score Placebo 484 289 530 315 63 117
25 g glucose 369 150 377 168 8 101
60 g glucose 434 334 485 346 52 162
Caffeine–glucose 374 215 403 250 29 102
Maths correct (number) Placebo 53 28 57 31 6 11
25 g glucose 41 15 41 17 0 9
60 g glucose 51 27 55 28 5 16
Caffeine–glucose 42 20 45 23 3 10
Maths errors (number) Placebo 4 4 4 4 0 3
25 g glucose 4 4 4 2 0 4
60 g glucose 7 13 7 14 1 4
Caffeine–glucose 5 7 5 9 0 2
Maths speeda (ms) Placebo 6047 3489 5208 2627 505 902
25 g glucose 5537 1471 5266 1871 387 1256
60 g glucose 4762 1851 4558 1711 39 751
Caffeine–glucose 5512 2206 4712 1781 927 1270
Stroop score Placebo 3431 1248 3588 1439 157 627
25 g glucose 3730 1328 4182 1362 353 798
60 g glucose 3235 1154 3542 1187 307 813
Caffeine–glucose 3561 1144 3975 1207 414 875
Stroop error (number) Placebo 1 2 2 3 1 3
25 g glucose 2 2 3 3 1 3
60 g glucose 3 5 4 5 1 3
Caffeine–glucose 2 2 3 5 0 2
Stroop speedb (ms) Placebo 1961 1462 1869 1624 135 238
25 g glucose 1700 539 1587 566 86 228
60 g glucose 1715 1054 1647 1050 68 253
Caffeine–glucose 1761 770 1515 599 218 278
Stroop misses (number) Placebo 27 13 27 14 0 4
25 g glucose 26 11 25 12 1 7
60 g glucose 30 12 29 13 1 6
Caffeine–glucose 26 12 27 12 1 5
Tracking score Placebo 429 59 415 80 14 86
25 g glucose 378 130 288 533 5 74
60 g glucose 358 183 378 99 11 108
Caffeine–glucose 384 129 362 166 21 102
Tracking timeouts (number) Placebo 36 41 46 66 2 48
25 g glucose 71 94 151 493 1 55
60 g glucose 87 152 65 67 6 77
Caffeine–glucose 64 79 76 103 11 75
Working memory score Placebo 4383 1863 5002 1989 619 1157
25 g glucose 4728 1863 5017 1843 289 1092
60 g glucose 5212 2037 6260 2451 845 1344
Caffeine–glucose 4639 2006 5232 2280 515 1142
Working memory responses (number) Placebo 504 232 559 264 43 93
25 g glucose 518 217 590 228 71 121
60 g glucose 556 198 590 215 34 129
Caffeine–glucose 595 221 713 273 96 134
Working memory errors (number) Placebo 20 28 26 39 4 10
25 g glucose 21 24 27 30 6 13
60 g glucose 23 22 26 29 1 12
Caffeine–glucose 18 16 27 22 9 15
Working memory timeouts (number) Placebo 38 15 36 15 1 7
25 g glucose 38 12 35 16 3 8
60 g glucose 37 12 36 14 1 6
Caffeine–glucose 36 12 33 14 3 8
Working memory speed (ms) Placebo 1695 1747 1600 1706 49 207
25 g glucose 1366 661 1229 517 100 306
(Continues)
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did not differ signiﬁcantly by condition. We cannot,
however, rule out the possibility that those in the
caffeine–glucose condition were able to change their
strategy to optimise their score. However, this seems
unlikely as the most effective strategy to increase
overall score is to focus on the working memory task,
and there was no evidence that this was the case. There
were signiﬁcant improvements to the speed of
performing mental arithmetic associated with the
caffeine–glucose drink. Those in the combination
drink were faster than either glucose drink alone, again
suggesting that caffeine conferred a beneﬁt to perfor-
mance. Mathematical processing requires manipula-
tion of information held in consciousness and, like
multi-tasking, draws heavily on working memory and
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Figure 3. Effects of treatment on multi-tasking performance. Bars show
mean change from baseline scores ± standard error of mean. **p< 0.01
Table 3. Summary statistics showing treatment effects (mean and SD) on mood measures
Baseline
pre-MTF
Baseline
post-MTF
Baseline
change
Treatment
pre-MTF
Treatment
post-MTF
Treatment
change
Change
pre-MTF change Δ
Mean SD Mean SD Mean SD Mean SD Mean SD Mean SD Mean SD Mean SD
Alert Placebo 57 20 59 17 2 15 66 15 65 18 1 16 8 19 2 20
25 g glucose 60 17 61 18 1 11 67 14 66 17 1 10 7 13 2 1
60 g glucose 56 20 53 19 3 18 60 17 59 20 1 16 4 17 2 20
Caffeine–glucose 63 18 60 19 3 16 71 14 66 16 5 15 9 14 2 18
Calm Placebo 67 16 58 20 9 18 58 65 54 19 4 16 9 20 6 22
25 g glucose 69 13 58 18 10 17 65 17 55 22 10 15 4 13 1 13
60 g glucose 64 17 57 16 8 16 60 16 55 16 5 13 4 18 3 17
Caffeine–glucose 70 15 59 18 12 13 61 20 59 21 2 20 9 16 10 17
Content Placebo 70 16 68 16 2 12 72 14 73 14 1 11 2 13 4 15
25 g glucose 70 15 69 15 1 10 73 13 72 15 2 8 3 9 1 10
60 g glucose 67 12 62 12 5 13 69 11 66 13 3 10 2 12 2 11
Caffeine–glucose 71 20 67 16 4 15 72 13 71 12 2 9 1 10 3 19
Fatigue Placebo 46 2.65 54 2.06 0.72 2.22 37 2.10 49 2.38 1.21 2.34 0.92 2.34 0.59 2.92
25 g glucose 41 2.29 52 2.09 1.14 1.98 36 1.85 50 2.28 1.42 1.99 0.47 1.48 0.33 2.18
60 g glucose 40 2.75 51 2.56 1.09 2.16 35 2.33 49 2.42 1.45 2.39 0.57 2.88 0.42 3.13
Caffeine–glucose 39 2.69 53 2.47 1.39 2.23 29 1.83 44 2.48 1.55 2.51 0.96 2.46 0.18 1.97
Stress Placebo 28 2.17 39 2.38 1.23 2.28 28 1.77 40 2.57 1.24 2.21 0.16 1.58 0.07 2.06
25 g glucose 26 1.98 39 1.99 1.31 2.02 29 1.94 41 2.24 1.22 2.02 0.24 1.94 0.04 1.79
60 g glucose 23 1.98 38 2.12 1.50 1.71 25 1.89 35 2.27 0.97 1.99 0.23 1.91 0.45 2.39
Caffeine–glucose 26 2.35 42 2.41 1.64 2.48 26 2.21 37 2.58 1.18 2.26 0.19 1.22 0.84 2.39
State anxiety Placebo 45 5.05 44 5.17 0.92 3.57 44 4.84 43 6.02 0.05 4.8 0.89 3.67 0.42 5.33
25 g glucose 45 5.60 43 5.06 1.49 4.01 43 5.25 44 5.3 0.4 3.09 1.65 3.67 1.89 5.13
60 g glucose 44 4.88 44 4.20 0.27 4.07 43 5.24 43 5.89 0 4.82 0.78 4.41 0.27 6.18
Caffeine–glucose 44 4.62 42 4.69 2.84 3.85 44 5.46 42 6.41 1.67 3.81 1 2.85 1.16 4.15
Table 2. (Continued)
Baseline Post-treatment Change from baseline
Mean SD Mean SD Mean SD
60 g glucose 1388 1199 1256 797 37 197
Caffeine–glucose 1251 669 1109 618 143 212
Working memory list retrieves (number) Placebo 3 8 3 8 0 1
25 g glucose 2 2 1 1 0 1
60 g glucose 1 1 1 1 0 1
Caffeine–glucose 2 3 1 2 1 1
Means with SDs are shown.
aSigniﬁcant main effect.
bTrend towards a main effect of treatment on change-from-baseline scores.
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executive processes. Taken together, these ﬁndings
suggest that the caffeine–glucose combination can im-
prove executive functioning through the allocation of
more attentional resources to multi-task performance.
There was also some evidence of improvements to
the speed of responding on the Stroop module. The
Stroop task is a classic measure of selective attention
and response inhibition. Again, effective performance
relies on executive responses—in this case, inhibiting
the response to the word meaning in favour of its per-
ceptual properties.
Counter to our hypotheses, there were no behav-
ioural effects of either dose of glucose alone. Those
in the 25 g glucose condition had numerically better
performance (although this did not approach statistical
signiﬁcance), whereas performance in the 60 g condi-
tion was similar to that in placebo and signiﬁcantly
worse than that in the caffeine–glucose drink. These
performance differences between the two glucose-only
conditions support the notion of an inverted U dose–
response curve for glucose on some aspects of cogni-
tion (Riby, 2004). With regard to speciﬁc outcomes,
in previous studies examining the effects of glucose
on sequentially performed tasks, 25 g glucose has im-
proved working memory (serial subtraction) perfor-
mance (Scholey et al., 2001). On the other hand,
performance of a task very similar to the working
memory module in the current study was unaffected
by 37.5 g glucose, either alone or in combination with
glucose (Scholey and Kennedy, 2004). Owen et al.
(2012) speciﬁcally compared the mood and cognitive
effects of 25 and 60 g glucose drinks. Her data reveal
a complex pattern of effects, with the two doses
interacting differentially with task type and fast dura-
tion. The 25 g drink was associated with better serial
sevens performance following a 2-h fast only, and
faster choice reaction times following an overnight fast
only. The 60 g dose speeded word recognition and
improved serial threes performance following an over-
night (but not 2 h) fast. None of the affected tasks were
a direct analogue of those in the current study. Never-
theless, we have previously argued that tasks that
require higher levels of mental effort for effective
Table 4. Summary statistics showing treatment effects (mean and SD) on measures derived from the NASA-TLX
Baseline Post-treatment Change from baseline
Mean SD Mean SD Mean SD
Mental demand Placebo 61 21 60 24 1 16
25 g glucose 63 18 58 24 4 19
60 g glucose 53 23 53 25 1 21
Caffeine–glucose 59 17 58 18 0 15
Physical demand Placebo 28 21 32 26 4 16
25 g glucose 29 22 27 20 2 13
60 g glucose 29 25 33 26 5 12
Caffeine–glucose 24 18 31 22 8 18
Temporal demand Placebo 65 20 62 25 3 22
25 g glucose 63 19 61 24 2 18
60 g glucose 60 17 55 22 5 19
Caffeine–glucose 60 18 55 21 5 15
Performance Placebo 34 17 32 16 3 19
25 g glucose 41 17 37 21 4 20
60 g glucose 44 22 40 22 4 20
Caffeine–glucose 35 20 33 22 2 23
Effort Placebo 68 18 65 19 2 11
25 g glucose 66 17 63 24 3 14
60 g glucose 64 21 62 20 2 18
Caffeine–glucose 62 18 56 21 7 17
Frustration Placebo 42 24 42 22 0 22
25 g glucose 36 23 36 24 0 16
60 g glucose 42 22 40 23 2 22
Caffeine–glucose 36 26 37 23 1 20
Table 5. Number of participants guessing which treatment they had
received by condition
Treatment guessed (N)
Placebo 25 g glucose 60 g glucose Caffeine–glucose
Placebo 6 15 8 8
25 g glucose 6 17 10 5
60 g glucose 8 14 14 3
Caffeine–glucose 7 12 6 11
p 0.938 0.826 0.298 0.142
p indicates probability of difference from chance values within each treat-
ment guessed.
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execution are more susceptible to the glucose enhance-
ment effect. It might be assumed that multi-tasking
would fall into this category, and indeed the mood
changes associated performing the MTF support this
contention. On the other hand, previous studies that
have found effects of glucose (usually 25 g) during
dual tasking have included more individual task such
as effortful psychomotor tracking (Scholey et al.,
2009b) or repeated, alternating hand movements
(Sünram-Lea et al., 2002). The effect may be because
such tasks are more effortful than the MTF used in
the current study, for example, co-performing hand
movements can reduce memory performance to near
chance levels (Scholey et al., 2013; Scholey et al.,
2006). Alternatively, previous dual tasking studies
have typically included a declarative memory compo-
nent, which may be more susceptible to the glucose-
related enhancement.
These positive effects seen here may be due to the
additive/synergistic effects of glucose and caffeine in
combination, supporting previous behavioural studies
showing that the effects of caffeine and glucose
together were signiﬁcantly better than those of either
substance alone (Scholey and Kennedy, 2004). Alter-
natively, at present, we cannot rule out the possibility
that they may be attributable to caffeine contained
within this treatment only. Future studies should com-
pare the effects of caffeine alone with the other treat-
ments used in the current study.
There were no mood changes associated with any
drink. This is consistent with much of the previous lit-
erature regarding glucose. However, caffeine is often
associated with alerting effects, although these are
most easily detected in individuals who are in a depri-
vation state owing to (e.g.) fatigue and are most readily
found with higher caffeine doses. In any case, these
ﬁndings suggest that the signiﬁcant improvement in
multi-tasking performance following the caffeine–
glucose drink reﬂects direct effects on performance
rather than a secondary effect of improved arousal/
alertness.
It is worth noting that the mean body mass index of
the participants is towards the high end of the normal
range (mean body mass index = 24.36, SD 4.47). We
have previously reported that body composition differ-
entially inﬂuences glucose absorption and possibly
cognitive responses to glucose (Owen et al., 2013).
Further work might usefully be directed to discerning
the effect of body composition on cognitive responses
to various nutritional interventions.
In summary, a drink containing 40mg caffeine/60 g
glucose improved performance of an ecologically valid
task of multi-tasking. As the same drink improved
aspects of executive functioning and attention, it is possible
that increased allocation of attentional resources underlie
this effect. Further work should be aimed at delineating
the underlying mechanisms of these effects, including the
use of functional brain imaging. It would be of great interest
to examine different levels of glucose in combination with
caffeine in order to determine the threshold levels of the
two substances for positive effects on multi-tasking.
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